Volpara Health’s origins go back to founding CEO Ralph Highnam’s breakthrough research in medical physics and artificial intelligence at the University of Oxford. Deeply affected by the loss of friends and family members to breast cancer, Ralph decided to apply his findings to breast imaging. In 2009, with his cofounders, he set up home base in Wellington, New Zealand. In this small city on the edge of the world, the Volpara journey began.
Since then, Volpara has seen tremendous growth by almost every measure. In the last three years alone, the team has quadrupled in size, its culture embracing those operating additional offices in Boston, Massachusetts and Seattle, Washington, USA. More and more customers, especially across North America, Australia, and New Zealand, can now provide personalized screening experiences to patients.
The company’s groundbreaking products now support a revolutionary new software platform. Underpinning these products are an ever-increasing number of patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. The products are also validated by a volume of peer-reviewed publications unrivaled in the breast screening industry. As the number of products increased, Volpara's scope expanded to include lung cancer screening. These intertwined areas of growth led to the company’s increased revenue and financial stability.
And a single constant thread runs through them all: an abiding dedication to helping save families from cancer.
Since then, Volpara has seen tremendous growth by almost every measure. In the last three years alone, the team has quadrupled in size, its culture embracing those operating additional offices in Boston, Massachusetts and Seattle, Washington, USA. More and more customers, especially across North America, Australia, and New Zealand, can now provide personalized screening experiences to patients.
The company’s groundbreaking products now support a revolutionary new software platform. Underpinning these products are an ever-increasing number of patents, trademarks, and regulatory clearances, including FDA clearance and CE marking. The products are also validated by a volume of peer-reviewed publications unrivaled in the breast screening industry. As the number of products increased, Volpara's scope expanded to include lung cancer screening. These intertwined areas of growth led to the company’s increased revenue and financial stability.
And a single constant thread runs through them all: an abiding dedication to helping save families from cancer.
